While ICON's earnings forecast dipped slightly, the consensus price target remains unchanged. Despite the slower expected revenue growth, ICON is still predicted to outperform the wider industry growth.
Upgrades •$Marqeta(MQ.US)$: Morgan Stanley Upgrades to Overweight from Equalweight - PT $15 •$西北天然氣(NWN.US)$: BofA Securities Upgrades to Neutral from Underperform - PT $53 (from $51) •$奧的斯(OTIS.US)$: Barclays Upgrades to Overweight from Equalweight - PT $82 (from $80) •$Snowflake(SNOW.US)$: Rosenblatt Upgrades to Buy from Neutral - PT $255 (from $325) Downgrades •$伊頓(ETN.US)$: Barclays Downgrades to Underweight from Eq...
$施貴寶(BMY.US)$$武田製藥(TAK.US)$$PPD Inc(PPD.US)$$Icon PLC(ICLR.US)$Anyone have any input on some of these Biotech and Research stocks below. Some of them are trading at pretty high prices. Yet a few of them are priced low and was wondering if now would be a good time to get in and hold for a long time. Thank you for any input or discussion. Bristol-Myers Squibb Company (BMY) Takeda Pharmaceutical Company (TAK) PPD Inc (PPD) ICON Public Limited Company (ICLR) Charles Rivers Laboratories International (CRL) Laboratory Corporation of America (LH) IDEXX Laboratories Inc (IDXX) Bio-Rad Laboratories Inc (BIO)
Icon PLC股票討論區
TOP WATCH AH + 7/27 ⚡️
利潤表有個非常不好的趨勢,最近利息費用高速增長,2022年達到2.3億,佔營業利潤的26%,負擔很重。
2023Q1營收增長4%,營業利潤增長27.5%,淨利潤受利息費用大幅增長影響僅增長了4.2%。
資產負債表顯示公司在2021年舉債54億進行大筆收購,商譽及其他無形資產從10億增長到138億,遠超淨資產。
2022年應收賬款增長7.3億到28億,增長部分超過當年5.05億淨利潤,佔當年營收的36%,比例和增速都極不健康,2023Q1應收賬款又增長1.8億,超過當季的1.2億淨利潤
目前市盈率40.2,市盈率TTM略降到39.8,可以多等幾份業績看看收購的效果以及應收賬款是否改善再判斷。
專欄Top upgrades and downgrades on 5/24
• $Marqeta(MQ.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $15
• $西北天然氣(NWN.US)$ : BofA Securities Upgrades to Neutral from Underperform - PT $53 (from $51)
• $奧的斯(OTIS.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $82 (from $80)
• $Snowflake(SNOW.US)$ : Rosenblatt Upgrades to Buy from Neutral - PT $255 (from $325)
Downgrades
• $伊頓(ETN.US)$ : Barclays Downgrades to Underweight from Eq...
專欄Top upgrades and downgrades on 4/12
• $Aptiv PLC(APTV.US)$ : Wells Fargo Upgrades to Equal Weight from Underweight - PT $112 (from $108)
• $ASM INTERNATIONAL NV SPON ADR EACH REP 1 ORD SHS(ASMIY.US)$ : Barclays Upgrades to Overweight from EqualWeight - PT $425 (from $300)
• $Brighthouse Financial(BHF.US)$ : Wells Fargo Upgrades to Equal Weight from Underweight - PT $54 (from $53)
• $卡地納健康(CAH.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $74 (from $54)
• $CrowdStrike(CRWD.US)$ : Goldman...
Biotech and Research Stocks
Bristol-Myers Squibb Company (BMY)
Takeda Pharmaceutical Company (TAK)
PPD Inc (PPD)
ICON Public Limited Company (ICLR)
Charles Rivers Laboratories International (CRL)
Laboratory Corporation of America (LH)
IDEXX Laboratories Inc (IDXX)
Bio-Rad Laboratories Inc (BIO)
good Q2 report
暫無評論